Pancreatic Cancer

 

ABI-007 for Metastatic Adenocarcinoma of the Pancreas (FHCRC-2350)
A Randomized Phase III Study of Weekly ABI-007 (Abraxane) plus Gemcitabine (Gemzar) versus Gemcitabine Alone in Patients with Metastatic Adenocarcinoma of the Pancreas

Investigator: Sunil Hingorani, MD, PhD;   Conditions: Pancreatic Cancer;    Status: Closed;   Study ID: NCT00844649